

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20201 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/887,465	06/22/2001	Edward B. Nelson	MCP-267	6932
27777	7590 10/02/2002			
	CIAMPORCERO JR.		EXAMINE	INER
JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933-7003			TRAVERS, F	RUSSELL S
			ART UNIT	PAPER NUMBER
			1617	6
			DATE MAILED: 10/02/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/887,465

Applicant(s)

Examiner

Russell Travers Art Unit

1617

Nelson et al



The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.					
 Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. 					
 If the period for reply specified above is less than thirty (30) days, a reply within the If NO period for reply is specified above, the maximum statutory period will apply a Failure to reply within the set or extended period for reply will, by statute, cause the Any reply received by the Office later than three months after the mailing date of the earned patent term adjustment. See 37 CFR 1.704(b). 	and will expire SIX (6) MONTHS from the mailing date of this communication. the application to become ABANDONED (35 U.S.C. § 133).				
Status					
1) Responsive to communication(s) filed on					
2a) ☐ This action is FINAL . 2b) ☒ This act	tion is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.					
Disposition of Claims					
4) 💢 Claim(s) <u>1-26</u>	is/are pending in the application.				
4a) Of the above, claim(s)	is/are withdrawn from consideration.				
5)	is/are allowed.				
6) Claim(s)	is/are rejected.				
7) Claim(s)	is/are objected to.				
8) 💢 Claims <u>1-26</u>	are subject to restriction and/or election requirement.				
Application Papers					
9) \square The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/are	e a) \square accepted or b) \square objected to by the Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
	is: a) \square approved b) \square disapproved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Exam	iner.				
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgement is made of a claim for foreign p	riority under 35 U.S.C. § 119(a)-(d) or (f).				
a) ☐ All b) ☐ Some* c) ☐ None of:					
1. Certified copies of the priority documents hav					
2. Certified copies of the priority documents hav					
 3. Copies of the certified copies of the priority deposition from the International Bure *See the attached detailed Office action for a list of the 	au (PCT Rule 17.2(a)).				
14) Acknowledgement is made of a claim for domestic					
a) The translation of the foreign language provisional					
15) Acknowledgement is made of a claim for domestic					
Attachment(s)	priority and 00 0.0.0. 33 120 and/or 121.				
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).				
2) Notice of Draftsperson's Patent Drawing Review (PTC-948)	5) Notice of Informal Patent Application (PTO-152)				
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Cther:				

Restriction to one of the following inventions is required under 35 U.S.C. § 121:

I. Claims 1-20 and 23-26, drawn to treating arteriosclerosis by therapeutically administering acetaminophen compounds and various anti-arteriosclerosis compounds concomitantly.

II. Claims 21-22, drawn to therapeutic compositions containing various acetaminophen compounds and additional anti-arteriosclerosis compounds concomitantly.

Claims contained in Groups I-II are directed to patentably unrelated therapeutic methods and compositions employing a plurality of patentably distinct compound species. Applicant is required under 35 U.S.C. § 121 to elect a single disclosed compound species, employed to practice the claims of the invention group chosen. Additionally, Applicants are required to identify those claims directed to this therapeutic method, or composition, employing the single compound species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.

Application/Control Number: 09/887,465 Page 3

Art Unit:

The above delineated inventions differ as unrelated compositions and therapeutic methods; and are independent and patentably distinct each from the other. The grouped inventions patentably distinct, a reference which would anticipate, or make obvious, the inventions of groups I-II would not necessarily obviate or anticipate the inventions in the other group. The searches are not co-inclusive as indicated by the diverse nature of the subject matter, thus, would represent an undue burden on Examiner. One skilled in the art would readily practice the invention of one of the above groups with out infringing and or practicing the invention of another group. The subject matter is unique and has acquired a separate status in the art and is fully capable of supporting separate patents. For the foregoing reasons restriction is proper for examination purposes.

Applicant is reminded that upon the cancellation of the claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. 1.48 (b) if one or more of the currently named inventors is no longer an inventor if at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently filed petition under 37 C.F.R. 1.48 (b) and by the fee required under 37 C.F.R. 1.17 (h).

Any inquiry concerning this communication should be directed to Russell Travers at telephone number (703) 308-4603.

